Literature DB >> 7917072

Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

M Abel1, W J Book, J B Eisenkraft.   

Abstract

Nondepolarising muscle relaxants block neuromuscular transmission, acting as antagonists of the nicotinic receptors at the neuromuscular junction. Their undesired effects are frequently caused by interaction with acetylcholine receptors outside this junction, and autonomic cardiovascular effects may result. Other adverse effects include anaphylactic or anaphylactoid reactions, and histamine release. Various disease states may present specific considerations in the use of nondepolarising muscle relaxants. Although many complications of these drugs (such as prolonged block or resistance) are easily treated, others may necessitate immediate intervention and vigorous therapy. Careful selection of an appropriate relaxant for a particular patient will usually prevent the occurrence of complications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917072     DOI: 10.2165/00002018-199410060-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  133 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases.

Authors:  D A Moneret-Vautrin; J L Guéant; L Kamel; M C Laxenaire; S el Kholty; J P Nicolas
Journal:  J Allergy Clin Immunol       Date:  1988-11       Impact factor: 10.793

3.  The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide.

Authors:  J M Wierda; J Szenohradszky; A P De Wit; G Zentai; S Agoston; M Kakas; U W Kleef; D K Meijer
Journal:  Eur J Anaesthesiol       Date:  1991-11       Impact factor: 4.330

4.  Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis.

Authors:  C J Parker; J M Hunter
Journal:  Br J Anaesth       Date:  1989-02       Impact factor: 9.166

5.  Transient inability to see.

Authors:  J E Peacock; A Padfield
Journal:  Anaesthesia       Date:  1988-11       Impact factor: 6.955

6.  Prolonged neuromuscular block after mivacurium.

Authors:  R S Petersen; P L Bailey; R Kalameghan; E R Ashwood
Journal:  Anesth Analg       Date:  1993-01       Impact factor: 5.108

7.  Local anesthetics and histrionicotoxin are allosteric inhibitors of the acetylcholine receptor. Studies of clonal muscle cells.

Authors:  S M Sine; P Taylor
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

8.  The site of the neuromuscular block produced by polymyxin B and rolitetracycline.

Authors:  J M Wright; B Collier
Journal:  Can J Physiol Pharmacol       Date:  1976-12       Impact factor: 2.273

9.  Modification of atracurium blockade by halothane and by suxamethonium. A review of clinical experience.

Authors:  J A Stirt; R L Katz; A L Murray; D L Schehl; C Lee
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

10.  Lithium and neuromuscular transmission.

Authors:  B E Waud; L Farrell; D R Waud
Journal:  Anesth Analg       Date:  1982-05       Impact factor: 5.108

View more
  2 in total

Review 1.  Adverse effects of neuromuscular blockers and their antagonists.

Authors:  M Naguib; M M Magboul
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 2.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.